New Findings Show COVID-19 Can Persist in Cancer Patients and Impact Treatments

Recent research conducted by the University of Minnesota Medical School has shed light on how COVID-19 can remain in the bodies of cancer patients long after initial infection, potentially influencing treatment outcomes. The study, published in iScience, focused on the persistent presence of the virus in gastrointestinal tissues of immunocompromised cancer patients, particularly those who had undergone transplant therapies. Researchers found that even six weeks after a positive nasal swab test, traces of the virus could still be detected in the gut lining. This lingering virus was associated with increased inflammation and tissue damage. Notably, a specific inflammatory marker, SERPINA1, was identified as being consistently linked to tissue inflammation in these cases.

The findings suggest that COVID-19’s persistence in the gastrointestinal tract might contribute to poorer outcomes during cancer treatment, especially in patients with elevated levels of inflammatory markers. Experts like Dr. Justin Hwang emphasized the potential importance of measuring GI tissue markers such as SERPINA1 before clinical decisions, particularly when considering transplantation therapies.

Furthermore, Dr. Emil Lou highlighted the significance of understanding if this persistent viral presence has longer-term effects, such as connections to Long COVID or other complications in this vulnerable population. The study underscores the need for further research involving larger cohorts to better understand the implications of persistent COVID-19 infection and the role of inflammation in cancer patients. Close monitoring may be necessary for patients with high SERPINA1 levels to mitigate increased inflammation risks associated with cancer treatments.

This study provides critical insights into the ongoing challenges posed by COVID-19 in immunocompromised patients, emphasizing the importance of tailored treatment strategies and further investigation into the virus’s long-term effects.